Leland Stanford Junior University

City of Hope

Ignacio Moraga Gonzalez

Kenan Christopher Garcia

Christine E Brown

K Christopher Garcia

Lawrence Stern

Xin Yang

Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13Rα2 than IL13Rα1 by virtue of weaker binding to IL13Rα1. The chimeric antigen receptors can be used to treat IL13Rα2 expressing cancers.

Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.

Therapeutic IL-13 polypeptides

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R&#x3b1;2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R&#x3b1;1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R&#x3b1; relative to the native human IL-13 protein.

Growing community of inventors

Palo Alto, CA, United States of America

Ignacio Moraga Gonzalez